Figure 2 depicts the quantity of each SGs protein component investigated in all investigations. G3BP1 has the greatest rate (16.9%), followed by eIF2α (13.4%), TIA-1 (9.2%), and eIF4G1 and FXR-1 (4.3%). Figure 3 is a schematic image of the proportion of anti-cancer medications utilized in studies in which bortezomib (26, 30, 39, 42, 59, 62, 63, 73) with 14% has the largest share and followed by 5-Fluorouracil (49, 54, 74), cisplatin (43, 48, 58), Oxaliplatin (26, 67, 76), and Sorafenib (24, 57, 62) with 5.3% of all anti-cancer medications used in studies. This evidence concerns the gene EIF2A and cancer.